Saturday, 22 June 2024

Australia's most trusted
source of pharma news

Saturday, 22 June 2024
Listen to this story 

New top-selling drug in the world

Posted 6 June 2024 AM

MSD's Keytruda rose to be the top-earning drug globally in 2023, a title ten years in the making. It was held at bay for years by AbbVie's mega-blockbuster Humira, which only fell when Pfizer's Covid vaccine Comirnaty surged to the top in the pandemic.

The PD-L1 inhibitor has been steadily growing thanks to MSD continually securing approvals for new indications. It's approved for more than 30 indications across various cancer types and stages around the world, including for 26 cancer types in Australia. However, it's reimbursed on the PBS for only 15 of those.

To see the whole article, please login

Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (29)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (7)

Other (20)

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.